2 results
Approved WMOCompleted
CORE PERIODPrimary:* Evaluate the safety and tolerability of up to 24 weeks of AG-348 administration in patients with pyruvate kinase deficiency (PK deficiency).Secondary:* Evaluate the pharmacokinetics (PK) of AG-348 and the metabolite AGI-8702.*…
Approved WMOCompleted
Primary Objective: The primary objective of this study is to assess lung volume measured by EIT and minute ventilation measured by the ventilator during CMV and FCV at the ICU. This will allow for an adequate powercalculation for future studies.…